Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0000899243-23-006735 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2023-03-01 | TNGX | Weber Barbara | CEO, Dir | A - Grant | $0.00 | +89.5K | 1.46M | +7% | $0 |
| D | 2023-03-02 | 2023-03-01 | TNGX | Weber Barbara | CEO, Dir | A - Grant | $0.00 | +537.3K | 537.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 89,545 | $0.00 | 1,457,137 | D | — | — | (F1) These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-03-01 | A | A | 537,273 | $0.00 | 537,273 | D | $5.20 · — to 2033-03-01 | 537,273 Common Stock | (F2) This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |